Borenius advised CapMan Buyout on the sale of Pharmia

We advised CapMan Buyout on the sale of Pharmia to Labomar, a leading European manufacturer of food supplements, medical devices and functional cosmetics, owned by Charterhouse Capital Partners. Labomar is headquartered in Italy with operations in Spain and Canada as well.

Pharmia is the leading contract manufacturer within food supplements and medical devices (CE-marked products) in the Nordics with a turnover of approximately 20 million euros and 85 employees. The company’s growth has been driven by a strategic focus on medical devices and probiotics, while simultaneously investing in R&D capabilities and operational efficiency improvements.